Haxdrax (ciclopirox olamine/salicylic acid)

The labeled strengths of ciclopirox olamine creams and lotions are no longer expressed in terms of the olamine salt (i.e., 1% ciclopirox olamine), but instead are expressed in terms of the base, ciclopirox (i.e., 0.77% ciclopirox).

Salicylic acid is applied topically to the skin as a cake, cream, gel, lotion, ointment, pledget, plaster, shampoo, solution, or suspension. Topical preparations of salicylic acid are for external use only. Contact with the eyes should be avoided; if contact occurs, the affected eye(s) should be washed thoroughly with water.

Prior to topical application, the affected area(s) to be treated should be cleansed and allowed to dry. Prior to removal of warts, corns, and calluses, the affected area may be soaked in warm water for 5 minutes.

Salicylic acid is commercially available in various preparations, some of which are intended for self-medication; the manufacturer's product labeling should be consulted for complete directions regarding appropriate dosage and administration of specific products.

Ciclopirox olamine is applied topically to the skin as a cream or lotion while ciclopirox is applied topically to the skin as a gel or shampoo and to nails as a solution (nail lacquer). The ciclopirox olamine lotion, which should be shaken vigorously before each use, may be particularly useful for infections involving relatively large areas or areas where a less viscous formulation might be preferred. Occlusive dressings or wrappings should not be used. Ciclopirox and ciclopirox olamine preparations should not be applied to the eye nor administered orally or intravaginally.

Patients should remove any loose nail or nail material (using nail clippers or nail files) before initiating therapy with ciclopirox solution (nail lacquer). Removal of unattached, infected nail(s) as frequently as once monthly by a qualified clinician in nail disorders, weekly self-trimming of infected nail(s) by the patient, and daily application of the topical solution (nail lacquer) are all essential components of the topical management of onychomycosis.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

• Aspirin exacerbated respiratory disease
• Hemolytic anemia from pyruvate kinase and g6PD deficiencies

There are no severe contraindications for this drug.

• No disease contraindications
• Peripheral vascular disease

There is no enhanced messaging for this drug.

Rare or Very Rare

• Anaphylaxis
• Burns
• Dyspnea
• Facial edema
• Hypersensitivity drug reaction
• Periorbital edema
• Pharyngeal edema
• Pruritus of skin
• Skin inflammation
• Skin irritation
• Skin ulcer
• Superficial skin ulcer
• Syncope
• Throat constriction
• Urticaria

More Frequent

• Stinging of skin

Less Frequent

• Dry skin
• Skin irritation

Rare or Very Rare

• Erythema
• Hair discoloration
• Nail disorders
• Pruritus of skin

No enhanced messaging available.

No enhanced messaging available.

There are no adequate and well-controlled studies of topical salicylic acid in pregnant women; the drug should be used during pregnancy only if the potential benefits justify the possible risks to the fetus.

Reproduction studies in mice, rats, rabbits, and monkeys using ciclopirox olamine dosages (via various routes of administration) 10 or more times the topical human dosage have not revealed evidence of harm to the fetus. Reproduction studies in rats and rabbits using topical dosages of ciclopirox up to 120 and 100 mg/kg of body weight, respectively, (approximately 121 and 147 times the maximum recommended topical human dosage based on surface area, respectively), also have not revealed evidence of fetotoxicity. In addition, reproduction studies in mice, rats, rabbits, and monkeys using oral dosages of ciclopirox up to 100, 30, 30, and 50 mg/kg of body weight, respectively (approximately 37.5, 30, 44, and 77 times the maximum recommended topical human dosage based on surface area, respectively), have not revealed evidence of fetotoxicity. There are no adequate and controlled studies to date using topical ciclopirox or ciclopirox olamine in pregnant women; topical ciclopirox olamine cream and lotion and ciclopirox shampoo should be used during pregnancy only when clearly needed, while topical ciclopirox gel and solution (nail lacquer) should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.

Because of the potential for serious adverse reactions to salicylic acid in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman. If used in nursing women, the drug should not be applied to the chest area to avoid accidental contamination of the infant.

It is not known whether ciclopirox or ciclopirox olamine is distributed in human milk. Because many drugs are distributed in human milk, ciclopirox or ciclopirox olamine preparations should be used with caution in nursing women.

No enhanced messaging available.